Advising SHINSEI CORPORATE INVESTMENT LIMITED (Japan) with respect to a bond investment in PROMETHERA BIOSCIENCES SA in the framework of its EUR 20 million bond issuance. PROMETHERA BIOSCIENCES SA is a clinical-stage R&D company focused on the research and development of cell-based therapies for liver diseases. The van Cutsem team was led by Benjamin Haberkorn
